Randomized studies testing the clinical efficacy of platelet additive solutions (PASs) for storage of platelets are scarce and often biased by patient selection. We conducted a multicenter, randomized study to investigate clinical efficacy of platelets stored in PAS II versus plasma, also including patients with clinical complications associated with increased platelet consumption. A total number of 168 evaluable patients received pooled buffy coat derived platelet concentrates (PC) suspended in either plasma (n = 354) or PAS II (n = 411), stored up to 5 days. Both univariate as well as multivariate analysis showed a significant effect of used storage medium in regard to 1-and 24 hour count increments and corrected count increments, in favour of plasma PCs. However, there were no significant differences between the groups regarding bleeding complications and transfusion interval. Adverse transfusion reactions occurred significantly less after transfusions with PAS II PCs (p = 0.04).
Introduction
The use of platelet concentrates (PC) for the prevention and treatment of bleeding complications in patients with thrombocytopenia, due to cytotoxic therapy or malignancies of the bone marrow, is generally accepted. Despite the use of prophylactic platelet transfusions, bleeding is a frequent complication and recommendations regarding the preferred transfusion regimen, the quantity and quality of transfused platelets and strategies to monitor efficacy differ and only a minority is evidence based. 1, 2 In recent decades storage of platelets suspended in non-plasma media (additive solutions) evolved as a growing field of interest. Possible advantages of using additive solutions instead of plasma are an increase of plasma available for plasma products, a reduction of plasma related adverse reactions, improvement of storage conditions in order to increase the shelf-life of PCs and allowing photochemical pathogen reduction techniques. In the Netherlands the National Blood Supply aims for harmonization of blood products used throughout the country. Currently, except when selected donors are required, all platelet products are prepared using the buffy coat (BC) method. On historical grounds two platelet products are used: Plasma stored platelet concentrates (Plasma PC) and platelet concentrates stored in Platelet Additive Solution II (PAS II PC, Trombosol, Baxter). However, there are no informative studies for a strong selection for one of these products. Although in vitro studies showed significant differences suggesting inferior quality in metabolic, functional and flowcytometric parameters in platelets stored in PAS-II as compared to plasma, platelets stored up to five days in PAS II stay within the range of minimal quality requirements. [3] [4] [5] [6] The correlation of these in vitro parameters with clinical efficacy is inconsistent. [7] [8] [9] One paired radiolabelled platelet survival study showed a significant decrease in both recovery as well as survival of PAS II PCs compared to plasma PCs and PCs stored in PlasmaLyte A. 10 Data regarding the clinical transfusion response of platelets stored in PAS II are also limited. A small, non-randomized clinical trial did not show a significant difference between PAS II PCs and plasma PCs, and one small prospective, randomized study reported that corrected count increments (CCIs) after transfusion with PAS II PCs were significantly lower. 11, 12 Despite lower CCIs bleeding complications did not differ and the latter study reported a significant reduction in transfusion reactions. 11 Observational analysis of the transfusion response of PAS II PCs and plasma PCs, used in the control arm of a randomized trial evaluating pathogen inactivated platelets (EuroSPRITE), did not show significant differences. 13, 14 Major drawback of these studies was the exclusion of patients with clinical factors known to increase platelet [12] [13] [14] Because several studies show the importance of patient related factors in relation to platelet transfusion response we performed a randomized, controlled, doubleblinded study to evaluate the therapeutic efficacy and safety of PAS II PCs in a non-selected patient population. [15] [16] [17] [18] [19] Patients and methods
Patients and study design
The study protocol was approved by the hospital ethics committees and conducted according to 
Platelet concentrates (PCs)
PCs were prepared from five-pooled whole blood BCs with the same ABO blood group. 22, 23 After collection of a unit of whole blood, BCs were prepared through high-speed centrifugation. Five BCs together with one unit of PAS II or one unit of plasma from one of the BC donors were coupled to a BC pool set (containing a transfer bag, leukocyte filter and a PL-2410 storage container, Baxter) through a sterile connection device. After connecting, the five BCs were pooled in the transfer bag together with the unit of PAS II or plasma. A low speed differential centrifugation was used to separate the platelet rich supernatant from erythrocytes and leucocytes, which subsequently was pressed through the leukocyte-filter into the storage container. A sample was obtained prior to storage to measure platelet content, pH and bacterial culture. The platelet content was measured using a Beckman Coulter Act-10 (Coulter Corp., Miami Florida, USA). The PCs were stored at 20-24 ˚C on a flatbed shaker up to 5 days. The PCs were γ irradiated with 25 Gy at time of issue in case of specific patient requirements for the prevention of transfusion-associated graft-versus-host disease.
Platelet transfusions and monitoring
The treating physician ordered platelet transfusions according to local hospital guidelines. In /l was used. Pre transfusion platelet count was measured one hour prior to transfusion.
Platelet counts were measured from 10 minutes to 2 hours after transfusion and from 16 to 24
hours after transfusion to determine the 1-and 24-hour increment, respectively. Platelet counts in the participating hospitals were measured using a Sysmex XE-2100 (Sysmex Corp., Kobe, Japan). In case of a second PC transfusion within 4 hours, both transfusions were considered to be part of one transfusion. If the 24-hour increment exceeded the 1-hour increment, combined with other signs of haematopoietic recovery, then the 24-hour increment value was excluded from analysis. PC transfusion failure was defined as a 1-hour CCI < 7.5
and/or a 24-hour CCI < 4. 
Study endpoints
The primary endpoints of the study protocol were the 1-and 24-hour CCI, calculated as 
Statistical methods
The study was designed as a two-armed non-inferiority study. The sample size calculation was based on data of patients enrolled in the two randomized trials concerning non-plasma storage media. 12, 13 The standard deviation of the mean 1-and 24-hour CCI was estimated as 
Results

Patient population
Between October 2003 and April 2005, 195 patients were randomized (plasma PC n = 95; PAS II PC n = 100). A total of 11 patients were excluded (plasma PC n = 7; PAS II PC n = 4) 7 of which 6 patients had HLA-alloantibodies and 1 patient had HPA-alloantibodies prior to the first transfusion, 1 patient developed refractoriness with proven HLA-alloantibodies after the second transfusion, 2 patients acquired an indication for CMV-negative blood products and 1 patient was transferred to another department. Although patients were randomized based on expected platelet transfusions, 16 patients did not receive any platelet transfusion during the inclusion period (plasma PC n = 4, PAS II PC n = 12), resulting in 168 patients, in which platelet transfusions could be evaluated (plasma PC n = 84; PAS II PC n = 84). There were no significant differences between the two study arms (i.e. patients with evaluable transfusions) regarding demographic characteristics, diagnosis, treatment and transfusion history (table 1) .
The same applied for the excluded, non-transfused patients in both groups. Splenomegaly was present in 17 patients (10.1%). The mean time on study for patients receiving PAS II PCs and plasma PCs was 20.7 +/-7.1 and 21.5 +/-8.6 days (p = 0.54), respectively. Twenty-one patients were randomized more than once (plasma PC n = 11; PAS II PC n = 10). There were no significant differences in the occurrence of febrile episodes, proven infections and mucosal damage, most often localised to the digestive system (painful oral lesions and diarrhoea).
Platelet transfusions: product parameters and increments
A total number of 765 PCs were transfused ( plasma PC n = 354; PAS II PC n = 411). A total of 684 PC transfusions could be evaluated (89%; Plasma PC n = 311, PAS II PC n = 373). In the PAS II PC group the 1-hour and 24-hour CCI could be calculated in 337 (90%) and 334 (90%) transfusions, respectively. In the plasma PC group this was the case in 274 (88%) and 282 (91%) transfusions. The missing CCIs were a result of missing data regarding pre count, 1-and/or 24-hour post count.
In 
analysis showed a 95% CI between 6.5 and 32.9% (p = 0.004), and the difference in 24-hour CCI resulted in a 95% CI between -2.4 and 38.1% (p = 0.09). A multivariate analysis as described in the methods section showed an independent effect of the used storage medium with regard to both count increments and CCIs. Plasma PCs and PAS II PCs resulted in a sufficient 1-hour CCI in 81.3%and 69.1% respectively (p < 0.0001). The 24-hour CCI was sufficient in 70.7% and 65.7% (p = 0.16). Considering the difference in platelet content of plasma PCs and PAS II PCs, we also performed a linear regression analysis of count increments and platelet dose confirming significant lower 1-and 24-hour count increments after transfusion of PAS II PCs (data not shown). Gamma irradiation had no significant effect on the transfusion responses of both PCs.
Bleeding complications, transfusion reactions and transfusion interval
The overall incidence of bleeding complications was 32.1%, consisting of 16.1% grade I, 14.3% grade II and 1.8% grade III. Grade IV bleeding was not observed. There were no differences between the two study groups. As a surrogate marker for bleeding we also calculated the mean transfused red cell concentrates per patient, no difference was observed.
A total number of 26 mild transfusion reactions were observed in 21 patients. Of these, 17 (5.5%) transfusion reactions were related to plasma PCs and 9 (2.4%) related to PAS II PCs (p = 0.04). Eight patients receiving PAS II PCs experienced transfusion reactions versus thirteen receiving plasma PCs (p = 0.35). One patient, receiving plasma PCs, complicated with repeated dyspnoea and wheezing, decided to end the study protocol and was further treated with plasma reduced hyper concentrated platelet products. Table 3 shows an overview of platelet and red cell transfusions and the calculated transfusion interval. There were no significant differences with regard to transfused PCs, interval and required red cell transfusions per patient. However, the platelet transfusion interval is substantially determined by timing of blood sampling and varying (logistic) delays in PC administration after reaching a transfusion trigger. 
Effects of storage
Discussion
With the intention to harmonise platelet products in the Netherlands and in anticipation to future product changes, we performed a randomised controlled trial comparing plasma PCs and PAS II PCs. With the exception of immunological refractoriness due to HLA-and HPAantibodies no exclusion criteria regarding factors of increased platelet consumption were used. There is general agreement that changes in platelet products should be validated for their clinical quality. Because major bleeding complications are rare, platelet count increments and CCIs have been accepted as surrogate endpoints. 24 A draft guidance for
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From testing and evaluating platelet components advises an array of in vitro tests, the use of in-vivo autologous radio labelled platelet survival studies and clinical trials, including haemostatic efficacy. 25 Currently, in Europe the requirements defined for quality control of platelet transfusion are minimal. In our study swirl, pH and platelet content were determined as in vitro parameters. Swirl was present in all transfused products. The platelet content of the products was measured directly after production as a previous study has shown a limited decline in platelet number during 5 days of storage. 4, 23 We found significant differences with regard to pH and platelet content of the two PCs. The lower pH of PAS II PCs is due to a lower intrinsic pH of PAS II, lower buffering capacity and higher lactate production. 23, 26 The lower platelet content of PAS II PCs can be explained by a viscosity-related difference in the platelet distribution during centrifugation, resulting in a less efficient separation. 23 We showed that the 1-and 24-hour CCIs of PAS II PCs were lower as compared to plasma PCs, with a mean difference of 19.7% and 17.8%, respectively. This effect remained after correcting for possible confounders in a multivariate analysis. Although the platelet content in PAS II PCs was significantly (approximately 5%) lower as compared to plasma PCs, this small difference is not clinically relevant and the transfused dose per kilogram (or per square meter) in both groups was similar. Univariate analysis of the effect of storage time showed a significant decrease in 1-hour and 24-hour CCI in both products, more pronounced in stored PAS II PCs, in contrast to the results of the study of de Wildt-Eggen. 12 The mechanism of this storage effect is unknown. Increased P-selectin expression and structural changes have been suggested as possible mechanisms. 5, 6 Whether such in vitro changes explain for the inferior increments of PAS II PCs remains unclear. 8, 9 To investigate the clinical relevance of the inferior CCI of PAS II PCs we compared the incidence of bleeding, transfusion interval, red cell concentrate usage and the occurrence of transfusion failure, the latter also in relation to patient factors. We did not observe significant [15] [16] [17] [18] [19] In our study over 75% of all PCs were transfused during episodes with clinical complications associated with increased platelet consumption and multivariate analysis showed that patient related factors annihilated the effects of the used storage medium in relation to transfusion failure.
Compared to other studies we found a relatively low percentage of transfusion reactions, although significantly less after transfusions with PAS II PCs (p = 0.04), confirming the results of de Wildt-Eggen. 12 Probably this percentage underestimates the real frequency due to the fact that most reactions are mild, whereas fever and chills are common symptoms in this category of patients.
In conclusion we showed that transfusion responses with PAS II PCs are significantly lower, but not inferior, as compared to plasma PCs. The biological significance of this observation is not significantly exceeding a 30% deterioration. A multivariate analysis showed that patient related factors annihilated the observed differences and there were no significant differences with regard to bleeding complications or PC consumption. Transfusion reactions were mild, infrequent and significantly lower with PAS II PCs. As most patients in need of supportive care temporarily experience factors leading to increased platelet consumption, we propose that future clinical trials studying experimental platelet products should include these patients.
We showed safety and efficacy of PAS II PCs in intensively treated patients, however plasma PCs show superior increments. To prevent a downward creep in future developed platelet products, we advise storage of platelets in plasma should be included as a reference in future trials. Table 2 Platelet product parameters, dosage and transfusion response For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
